首页 > 最新文献

Quarterly reviews on drug metabolism and drug interactions最新文献

英文 中文
Hepatic drug metabolism in pregnancy. 妊娠期肝脏药物代谢。
Pub Date : 1984-01-01 DOI: 10.1515/dmdi.1984.5.1.53
B H Stock

The results of both isolated tissue and whole animal experimentation, whilst showing some unexplored inconsistencies, suggest that late pregnancy is associated with a reduced ability of the liver to metabolise foreign compounds. The mechanism of this reduced capacity and the physiological reason for it are unclear but such change does have implication for therapeutic response in pregnancy. Available results from the limited and often poorly structured studies of drug levels in pregnant women neither prove nor disprove the existence of similar changes in hepatic monooxygenase activity during human pregnancy.

分离组织和整个动物实验的结果,虽然显示出一些未被发现的不一致之处,但表明妊娠后期与肝脏代谢外来化合物的能力下降有关。这种能力降低的机制和生理原因尚不清楚,但这种变化确实对妊娠期的治疗反应有影响。对孕妇药物水平的有限且结构不完善的研究得出的现有结果既不能证明也不能否定人类妊娠期间肝脏单加氧酶活性存在类似变化。
{"title":"Hepatic drug metabolism in pregnancy.","authors":"B H Stock","doi":"10.1515/dmdi.1984.5.1.53","DOIUrl":"https://doi.org/10.1515/dmdi.1984.5.1.53","url":null,"abstract":"<p><p>The results of both isolated tissue and whole animal experimentation, whilst showing some unexplored inconsistencies, suggest that late pregnancy is associated with a reduced ability of the liver to metabolise foreign compounds. The mechanism of this reduced capacity and the physiological reason for it are unclear but such change does have implication for therapeutic response in pregnancy. Available results from the limited and often poorly structured studies of drug levels in pregnant women neither prove nor disprove the existence of similar changes in hepatic monooxygenase activity during human pregnancy.</p>","PeriodicalId":79248,"journal":{"name":"Quarterly reviews on drug metabolism and drug interactions","volume":"5 1","pages":"53-81"},"PeriodicalIF":0.0,"publicationDate":"1984-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1515/dmdi.1984.5.1.53","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17458295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Metabolism and pharmacokinetics of hydroxyethylated rutosides in animals and man. 羟乙基化芦果苷在动物和人体内的代谢和药代动力学。
Pub Date : 1984-01-01 DOI: 10.1515/dmdi.1984.5.1.1
L P Balant, M Wermeille, L A Griffiths
{"title":"Metabolism and pharmacokinetics of hydroxyethylated rutosides in animals and man.","authors":"L P Balant,&nbsp;M Wermeille,&nbsp;L A Griffiths","doi":"10.1515/dmdi.1984.5.1.1","DOIUrl":"https://doi.org/10.1515/dmdi.1984.5.1.1","url":null,"abstract":"","PeriodicalId":79248,"journal":{"name":"Quarterly reviews on drug metabolism and drug interactions","volume":"5 1","pages":"1-24"},"PeriodicalIF":0.0,"publicationDate":"1984-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1515/dmdi.1984.5.1.1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17458294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 16
Drug interactions involving cimetidine--mechanisms, documentation, implications. 涉及西咪替丁的药物相互作用——机制、文献、影响。
Pub Date : 1984-01-01 DOI: 10.1515/dmdi.1984.5.1.25
W Greene

In summary, cimetidine is a potent inhibitor of liver microsomal activity, which may also decrease hepatic blood flow. Other effects of the drug include inhibition of gastric secretion and intrinsic toxic properties. These effects, combined with the common use of cimetidine in clinical practice, make the risk of adverse drug interactions a relatively frequent risk in the clinical setting. Although a multitude of interactions with cimetidine has been evaluated, many of these are incompletely described or understood. At the present time, a potentially significant alteration of absorption appears to exist with only ketoconazole, elemental iron, vitamin B12 (long-term therapy), and pancreatic enzyme supplements (increased activity). Significant metabolic inhibition or decreased excretion appears to exist with warfarin, propranolol, theophylline, phenytoin, quinidine, possibly lidocaine and procainamide, and certain benzodiazepines. Other potential, but less well ascertained interactions may involve the narcotic analgesics, caffeine, ethanol, pentobarbital, imipramine, chlormethiazole, and metronidazole. In these settings, the clinician must be aware of interaction potential, and astutely monitor the patient during combination therapy. Other data indicate that concomitant administration of antacids may reduce the absorption of cimetidine, that the drug may protect against the toxic effects of acetaminophen overdose, and that combination with certain other myelosuppressants may carry a significant risk. Thus, in regard to these reports, cimetidine is a drug with complex effects on the absorption, elimination, and toxicity of other drugs. When used in the setting of multiple drug therapy, the clinician must be alert to potentially increased or decreased effects of the drugs mentioned in this review. In addition, one must be aware that other hepatically metabolised agents not mentioned here may be affected by the addition of cimetidine therapy. Because of the therapeutic successes demonstrated in the treatment of various disorders with cimetidine, one cannot disregard this agent. Thus, the responsibility for understanding and monitoring for the complex effects of this drug falls with the practicing physician.

总之,西咪替丁是一种有效的肝微粒体活性抑制剂,它也可能减少肝血流。该药的其他作用包括抑制胃分泌和内在毒性。这些影响,加上临床实践中西咪替丁的普遍使用,使得药物不良相互作用的风险在临床环境中相对频繁。虽然已经评估了与西咪替丁的多种相互作用,但其中许多相互作用尚未完全描述或理解。目前,似乎只有酮康唑、铁元素、维生素B12(长期治疗)和胰酶补充剂(活性增加)对吸收有潜在的显著改变。华法林、心得安、茶碱、苯妥英、奎尼丁、可能还有利多卡因和普鲁卡因酰胺以及某些苯二氮卓类药物似乎存在明显的代谢抑制或排泄减少。其他潜在但不太确定的相互作用可能涉及麻醉性镇痛药、咖啡因、乙醇、戊巴比妥、丙咪嗪、氯甲咪唑和甲硝唑。在这些情况下,临床医生必须意识到相互作用的可能性,并在联合治疗期间敏锐地监测患者。其他数据表明,同时服用抗酸剂可能会减少西咪替丁的吸收,该药物可能会防止对乙酰氨基酚过量的毒性作用,并且与某些其他骨髓抑制剂合用可能会带来重大风险。因此,就这些报告而言,西咪替丁是一种对其他药物的吸收、消除和毒性具有复杂影响的药物。当用于多种药物治疗时,临床医生必须警惕本综述中提到的药物可能增加或减少的作用。此外,必须注意的是,这里没有提到的其他肝脏代谢药物可能会受到西咪替丁治疗的影响。由于用西咪替丁治疗各种疾病的治疗成功,人们不能忽视这种药物。因此,了解和监测这种药物的复杂影响的责任落在执业医师身上。
{"title":"Drug interactions involving cimetidine--mechanisms, documentation, implications.","authors":"W Greene","doi":"10.1515/dmdi.1984.5.1.25","DOIUrl":"https://doi.org/10.1515/dmdi.1984.5.1.25","url":null,"abstract":"<p><p>In summary, cimetidine is a potent inhibitor of liver microsomal activity, which may also decrease hepatic blood flow. Other effects of the drug include inhibition of gastric secretion and intrinsic toxic properties. These effects, combined with the common use of cimetidine in clinical practice, make the risk of adverse drug interactions a relatively frequent risk in the clinical setting. Although a multitude of interactions with cimetidine has been evaluated, many of these are incompletely described or understood. At the present time, a potentially significant alteration of absorption appears to exist with only ketoconazole, elemental iron, vitamin B12 (long-term therapy), and pancreatic enzyme supplements (increased activity). Significant metabolic inhibition or decreased excretion appears to exist with warfarin, propranolol, theophylline, phenytoin, quinidine, possibly lidocaine and procainamide, and certain benzodiazepines. Other potential, but less well ascertained interactions may involve the narcotic analgesics, caffeine, ethanol, pentobarbital, imipramine, chlormethiazole, and metronidazole. In these settings, the clinician must be aware of interaction potential, and astutely monitor the patient during combination therapy. Other data indicate that concomitant administration of antacids may reduce the absorption of cimetidine, that the drug may protect against the toxic effects of acetaminophen overdose, and that combination with certain other myelosuppressants may carry a significant risk. Thus, in regard to these reports, cimetidine is a drug with complex effects on the absorption, elimination, and toxicity of other drugs. When used in the setting of multiple drug therapy, the clinician must be alert to potentially increased or decreased effects of the drugs mentioned in this review. In addition, one must be aware that other hepatically metabolised agents not mentioned here may be affected by the addition of cimetidine therapy. Because of the therapeutic successes demonstrated in the treatment of various disorders with cimetidine, one cannot disregard this agent. Thus, the responsibility for understanding and monitoring for the complex effects of this drug falls with the practicing physician.</p>","PeriodicalId":79248,"journal":{"name":"Quarterly reviews on drug metabolism and drug interactions","volume":"5 1","pages":"25-51"},"PeriodicalIF":0.0,"publicationDate":"1984-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1515/dmdi.1984.5.1.25","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17218650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 19
Species differences in cytochromes P450 and their corresponding messenger RNA's. 细胞色素P450及其相应信使RNA的物种差异。
Pub Date : 1982-01-01 DOI: 10.1515/dmdi.1982.4.2-3.123
R Makowski, R Davies, G G Gibson
{"title":"Species differences in cytochromes P450 and their corresponding messenger RNA's.","authors":"R Makowski,&nbsp;R Davies,&nbsp;G G Gibson","doi":"10.1515/dmdi.1982.4.2-3.123","DOIUrl":"https://doi.org/10.1515/dmdi.1982.4.2-3.123","url":null,"abstract":"","PeriodicalId":79248,"journal":{"name":"Quarterly reviews on drug metabolism and drug interactions","volume":"4 2-3","pages":"123-70"},"PeriodicalIF":0.0,"publicationDate":"1982-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1515/dmdi.1982.4.2-3.123","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17819925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
The metabolism of drugs by isolated hepatocytes. 分离肝细胞对药物的代谢。
Pub Date : 1982-01-01 DOI: 10.1515/dmdi.1982.4.2-3.99
J R Fry

Isolated hepatocytes are being increasingly used in drug metabolism studies since they possess many of the attributes of both in vitro and in vivo systems. This paper reviews recent work on this use of isolated hepatocytes, with particular emphasis on their value in the study of (a) species and organ differences in xenobiotic metabolism, (b) the relation of metabolism to toxicity and (c) the balance of Phase I/Phase II metabolism.

由于分离的肝细胞具有体外和体内系统的许多特性,因此越来越多地用于药物代谢研究。本文综述了近年来分离肝细胞在这方面的研究,特别强调了它们在研究(a)异种代谢中的物种和器官差异,(b)代谢与毒性的关系以及(c) I/ II期代谢平衡方面的价值。
{"title":"The metabolism of drugs by isolated hepatocytes.","authors":"J R Fry","doi":"10.1515/dmdi.1982.4.2-3.99","DOIUrl":"https://doi.org/10.1515/dmdi.1982.4.2-3.99","url":null,"abstract":"<p><p>Isolated hepatocytes are being increasingly used in drug metabolism studies since they possess many of the attributes of both in vitro and in vivo systems. This paper reviews recent work on this use of isolated hepatocytes, with particular emphasis on their value in the study of (a) species and organ differences in xenobiotic metabolism, (b) the relation of metabolism to toxicity and (c) the balance of Phase I/Phase II metabolism.</p>","PeriodicalId":79248,"journal":{"name":"Quarterly reviews on drug metabolism and drug interactions","volume":"4 2-3","pages":"99-122"},"PeriodicalIF":0.0,"publicationDate":"1982-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1515/dmdi.1982.4.2-3.99","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17819928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Specific covalent binding and toxicity of aliphatic halogenated xenobiotics. 脂肪族卤化异种生物的特异性共价结合和毒性。
Pub Date : 1982-01-01 DOI: 10.1515/dmdi.1982.4.1.1
R J Laib
{"title":"Specific covalent binding and toxicity of aliphatic halogenated xenobiotics.","authors":"R J Laib","doi":"10.1515/dmdi.1982.4.1.1","DOIUrl":"https://doi.org/10.1515/dmdi.1982.4.1.1","url":null,"abstract":"","PeriodicalId":79248,"journal":{"name":"Quarterly reviews on drug metabolism and drug interactions","volume":"4 1","pages":"1-48"},"PeriodicalIF":0.0,"publicationDate":"1982-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1515/dmdi.1982.4.1.1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17815078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 15
Differences in the ferrihemoglobin-forming capabilities and carcinogenicities between monocyclic and polycyclic N-acylarylamines and their derivatives. 单环和多环n-酰基胺及其衍生物在铁血红蛋白形成能力和致癌性方面的差异。
Pub Date : 1982-01-01 DOI: 10.1515/dmdi.1982.4.2-3.171
W Lenk, H Sterzl
{"title":"Differences in the ferrihemoglobin-forming capabilities and carcinogenicities between monocyclic and polycyclic N-acylarylamines and their derivatives.","authors":"W Lenk,&nbsp;H Sterzl","doi":"10.1515/dmdi.1982.4.2-3.171","DOIUrl":"https://doi.org/10.1515/dmdi.1982.4.2-3.171","url":null,"abstract":"","PeriodicalId":79248,"journal":{"name":"Quarterly reviews on drug metabolism and drug interactions","volume":"4 2-3","pages":"171-236"},"PeriodicalIF":0.0,"publicationDate":"1982-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1515/dmdi.1982.4.2-3.171","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17819926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
A new class of non-hormonal contragestational agents: pharmacodynamic-pharmacokinetic relationships. 一类新的非激素类抗凝药物:药效学-药代动力学关系。
Pub Date : 1982-01-01 DOI: 10.1515/dmdi.1982.4.2-3.237
A Assandri, A Omodei-Salé, G Galliani
{"title":"A new class of non-hormonal contragestational agents: pharmacodynamic-pharmacokinetic relationships.","authors":"A Assandri,&nbsp;A Omodei-Salé,&nbsp;G Galliani","doi":"10.1515/dmdi.1982.4.2-3.237","DOIUrl":"https://doi.org/10.1515/dmdi.1982.4.2-3.237","url":null,"abstract":"","PeriodicalId":79248,"journal":{"name":"Quarterly reviews on drug metabolism and drug interactions","volume":"4 2-3","pages":"237-61"},"PeriodicalIF":0.0,"publicationDate":"1982-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1515/dmdi.1982.4.2-3.237","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17819927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 9
Drug-pyridoxal phosphate interactions. 药物-磷酸吡哆醛相互作用。
Pub Date : 1982-01-01 DOI: 10.1515/dmdi.1982.4.4.289
M Ebadi, C F Gessert, A Al-Sayegh

In this review it has been pointed out that vitamin B6 and its vitamers can be involved in many interactions with a number of drugs, as well as with the actions of various endocrines and neurotransmitters. Nutritional deficiencies, especially of vitamins and proteins, can affect the manner in which drugs undergo biotransformation, and thereby may also modify the therapeutic efficacy of certain drugs. The differences between nutritional vitamin B6 deficiency and the hereditary disorder producing pyridoxine dependency are discussed. In addition to a pyridoxine deficiency being able to adversely affect drug actions, the improper supplementation with vitamin B6 can in some instances also adversely affect drug efficacy. A decrease by pyridoxine in the efficacy of levodopa used in the treatment of Parkinsonism is an example. The interrelationships and enzymatic interconversions among pyridoxine vitamers, both phosphorylated and non-phosphorylated, are briefly discussed, particularly regarding their pharmacokinetic properties. The ways in which the normal biochemical functions of vitamin B6 may be interfered with by various drugs are reviewed. (1) The chronic administration of isoniazid for the prevention or treatment of tuberculosis can produce peripheral neuropathy which can be prevented by the concurrent administration of pyridoxine. An acute toxic overdose of isoniazid causes generalized convulsions, and the intravenous administration of pyridoxine hydrochloride will prevent or stop these seizures. (2) The acute ingestion of excessive monosodium glutamate will, in some individuals, cause a group of symptoms including among others headache, weakness, stiffness, and heartburn, collectively known as the 'Chinese Restaurant Syndrome.' These symptoms can be prevented by prior supplementation with vitamin B6. The beneficial effect is ascribed to the correction of a deficiency in the activity of glutamic oxaloacetic transaminase, an enzyme that is dependent on pyridoxal phosphate. Some interesting relationships are pointed out between vitamin B6, picolinic acid, and zinc. It is postulated that the intestinal absorption of zinc is facilitated by picolinic acid, a metabolite of tryptophan. The derivation of picolinic acid from tryptophan depends on the action of the enzyme kynureninase, which is dependent on pyridoxal phosphate; therefore, the adequate absorption of zinc is indirectly dependent on an adequate supply of vitamin B6. The formation of pyridoxal phosphate, on the other hand, appears to be indirectly dependent on Zn2++ which activates pyridoxal kinase.(ABSTRACT TRUNCATED AT 400 WORDS)

本文综述了维生素B6及其维生素类化合物与多种药物的相互作用,以及与多种内分泌和神经递质的作用。营养缺乏,特别是维生素和蛋白质的缺乏,会影响药物进行生物转化的方式,从而也可能改变某些药物的治疗效果。讨论了营养性维生素B6缺乏症与产生吡哆醇依赖性的遗传性疾病之间的差异。除了吡哆醇缺乏会对药物作用产生不利影响外,在某些情况下,维生素B6的不当补充也会对药物功效产生不利影响。吡哆醇降低左旋多巴治疗帕金森病的疗效就是一个例子。简要讨论了吡哆醇维生素之间的相互关系和酶转化,包括磷酸化和非磷酸化,特别是关于它们的药代动力学性质。综述了各种药物对维生素B6正常生化功能的干扰。(1)长期服用异烟肼预防或治疗结核可产生周围神经病变,可通过同时服用吡哆醇来预防。急性中毒过量服用异烟肼可引起全身抽搐,静脉注射盐酸吡哆醇可预防或停止抽搐。(2)某些人急性摄入过量的味精会引起一系列症状,包括头痛、虚弱、僵硬和胃灼热,统称为“中餐馆综合症”。这些症状可以通过事先补充维生素B6来预防。这种有益的作用归因于纠正了谷草酰乙酸转氨酶活性的不足,谷草酰乙酸转氨酶是一种依赖于磷酸吡哆醛的酶。指出了维生素B6、吡啶酸和锌之间的一些有趣的关系。据推测,锌的肠道吸收是由色氨酸的代谢物吡啶酸促进的。色氨酸衍生吡啶酸依赖于犬尿氨酸酶的作用,而犬尿氨酸酶依赖于磷酸吡哆醛;因此,锌的充分吸收间接依赖于维生素B6的充足供应。另一方面,吡哆醛磷酸的形成似乎间接依赖于活化吡哆醛激酶的Zn2++。(摘要删节为400字)
{"title":"Drug-pyridoxal phosphate interactions.","authors":"M Ebadi,&nbsp;C F Gessert,&nbsp;A Al-Sayegh","doi":"10.1515/dmdi.1982.4.4.289","DOIUrl":"https://doi.org/10.1515/dmdi.1982.4.4.289","url":null,"abstract":"<p><p>In this review it has been pointed out that vitamin B6 and its vitamers can be involved in many interactions with a number of drugs, as well as with the actions of various endocrines and neurotransmitters. Nutritional deficiencies, especially of vitamins and proteins, can affect the manner in which drugs undergo biotransformation, and thereby may also modify the therapeutic efficacy of certain drugs. The differences between nutritional vitamin B6 deficiency and the hereditary disorder producing pyridoxine dependency are discussed. In addition to a pyridoxine deficiency being able to adversely affect drug actions, the improper supplementation with vitamin B6 can in some instances also adversely affect drug efficacy. A decrease by pyridoxine in the efficacy of levodopa used in the treatment of Parkinsonism is an example. The interrelationships and enzymatic interconversions among pyridoxine vitamers, both phosphorylated and non-phosphorylated, are briefly discussed, particularly regarding their pharmacokinetic properties. The ways in which the normal biochemical functions of vitamin B6 may be interfered with by various drugs are reviewed. (1) The chronic administration of isoniazid for the prevention or treatment of tuberculosis can produce peripheral neuropathy which can be prevented by the concurrent administration of pyridoxine. An acute toxic overdose of isoniazid causes generalized convulsions, and the intravenous administration of pyridoxine hydrochloride will prevent or stop these seizures. (2) The acute ingestion of excessive monosodium glutamate will, in some individuals, cause a group of symptoms including among others headache, weakness, stiffness, and heartburn, collectively known as the 'Chinese Restaurant Syndrome.' These symptoms can be prevented by prior supplementation with vitamin B6. The beneficial effect is ascribed to the correction of a deficiency in the activity of glutamic oxaloacetic transaminase, an enzyme that is dependent on pyridoxal phosphate. Some interesting relationships are pointed out between vitamin B6, picolinic acid, and zinc. It is postulated that the intestinal absorption of zinc is facilitated by picolinic acid, a metabolite of tryptophan. The derivation of picolinic acid from tryptophan depends on the action of the enzyme kynureninase, which is dependent on pyridoxal phosphate; therefore, the adequate absorption of zinc is indirectly dependent on an adequate supply of vitamin B6. The formation of pyridoxal phosphate, on the other hand, appears to be indirectly dependent on Zn2++ which activates pyridoxal kinase.(ABSTRACT TRUNCATED AT 400 WORDS)</p>","PeriodicalId":79248,"journal":{"name":"Quarterly reviews on drug metabolism and drug interactions","volume":"4 4","pages":"289-331"},"PeriodicalIF":0.0,"publicationDate":"1982-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1515/dmdi.1982.4.4.289","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17154833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 20
Volatile anaesthetic metabolism and acute toxicity. 挥发性麻醉代谢和急性毒性。
Pub Date : 1982-01-01 DOI: 10.1515/dmdi.1982.4.1.49
J L Plummer, M J Cousins, P Hall
{"title":"Volatile anaesthetic metabolism and acute toxicity.","authors":"J L Plummer,&nbsp;M J Cousins,&nbsp;P Hall","doi":"10.1515/dmdi.1982.4.1.49","DOIUrl":"https://doi.org/10.1515/dmdi.1982.4.1.49","url":null,"abstract":"","PeriodicalId":79248,"journal":{"name":"Quarterly reviews on drug metabolism and drug interactions","volume":"4 1","pages":"49-98"},"PeriodicalIF":0.0,"publicationDate":"1982-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1515/dmdi.1982.4.1.49","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17815079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 11
期刊
Quarterly reviews on drug metabolism and drug interactions
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1